The Cooper Companies, Inc. (COO)
Juste valeurFondamental
67
Prix
$57.37
Capitalisation boursière
$10.53B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Cooper Companies makes two very different kinds of medical products under one roof: contact lenses, sold through eye-care professionals to people who need vision correction, and instruments and devices used in women's health and fertility clinics — from surgical tools to the equipment IVF labs use to handle embryos. The two businesses share little beyond a corporate parent and a fiscal calendar.
Comment l'entreprise gagne de l'argent
The lens business is a recurring-purchase model: contact lenses wear out and are reordered regularly, so once a patient is fitted with a brand, replacement sales tend to continue for years. The surgical and fertility business instead sells instruments, disposable devices and lab equipment to clinics and hospitals — some of it capital equipment bought once, some of it consumables reordered with each procedure. Growth in each half of the company depends on different things: population trends in vision correction for one, and clinic capacity and IVF cycle volumes for the other.
Chiffre d'affaires par segment
Soft contact lenses, including daily-disposable and specialty lenses that slow the progression of myopia in children.
Surgical instruments and devices for women's health, plus lab equipment and consumables used in fertility clinics for IVF.
Avantage concurrentiel
Coûts de changement · ÉtroitA patient fitted and comfortable with a specific contact lens rarely switches brands on their own initiative, and an eye-care professional who has standardized on a fitting set has a mild reason to keep prescribing it. Neither habit is unbreakable: a competing lens of similar quality, or a clinic's own procurement decision, can still displace it.
Ce qui stimule la demande
DéfensifVision correction is an ongoing need regardless of the economy, which supports the lens business through downturns. The fertility side is more sensitive to discretionary spending and to clinics' own capital budgets: equipment purchases can be postponed when clinics turn cautious, even if underlying procedure demand holds up.
Principaux risques
- Competition from larger diversified companies — In women's health and fertility, CooperSurgical competes against much larger medical-device companies with broader product lines and greater resources, which can give them an edge in marketing and bundled deals.
- Reimbursement and pricing pressure — Changes in third-party coverage and reimbursement, and pricing pressure from competitors, can reduce demand or margins on both contact lenses and medical devices.
- Clinic capital spending cycles — Fertility clinics have shown caution in equipment purchases in soft periods, which slows CooperSurgical's capital-equipment sales even when procedure volumes are stable.
Les arguments en faveur
Buyers argue that steady population growth in myopia and an ageing population needing vision correction give CooperVision durable demand, that specialty myopia-control lenses carry better pricing than commodity lenses, and that CooperSurgical's fertility business benefits from a long-term rise in IVF procedure volumes.
Les arguments contre
Sellers fear that contact lenses are a largely commoditized product exposed to pricing pressure from larger competitors, that combining two unrelated businesses under one roof makes capital allocation harder to judge from outside, and that fertility clinics' capital spending can stay soft for longer than expected.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
Alcon sells daily and monthly soft contact lenses and lens care solutions to the same eye-care practitioners and wearers CooperVision supplies worldwide, and Cooper's 10-K names it as one of its three primary contact lens rivals.
Its Acuvue brand is the largest seller of soft contact lenses and competes head-on with CooperVision in spherical, toric and multifocal lenses, while J&J's surgical and women's health devices also overlap with CooperSurgical.
Hologic sells diagnostic and surgical devices for gynaecology — including endometrial and uterine procedures — to the same OB/GYN offices and hospital departments CooperSurgical's medical devices serve.
Bausch + Lomb competes for the same optometrists and lens wearers with its Biotrue and Ultra contact lens lines and related lens care products, and is the third rival Cooper names in its 10-K.
Vitrolife sells embryo culture media, oils, consumables and reproductive genetic testing to the same IVF clinics and fertility labs that buy CooperSurgical's ART products.
Bayer's Mirena and Kyleena hormonal intrauterine devices compete directly with CooperSurgical's Paragard copper IUD for the same long-acting contraception prescriptions.
Bilan & Liquidités
Chiffre d'affaires
$4.24B
12 derniers mois (au 31/07/2026)
Résultat net
$570M
12 derniers mois (au 31/07/2026)
Flux de trésorerie libre
$434M
Capitaux propres totaux
$8.24B
Passif total
$4.16B
Ratio de liquidité général
1.22
Couverture des intérêts
6.10
Dette/EBITDA
2.99
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$54.28
Prix actuel
$57.37
Marge de sécurité
-5.7%
Fourchette de juste valeur
$38.20 - $70.35
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
19.36
ROE
4.6%
Ratio P/B
1.29
P/FCF
15.85
Marge brute
65.9%
ROIC
4.0%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
4.0%
WACC
7.5%
ROIC − WACC
-3.6 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (18)
- EPS shows upward trend
- Gross Margin 65.9%
- P/FCF 15.85
- P/B Ratio 1.29
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 11.0%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 4.8%
- Earnings Quality (OCF/NI) 1.81
- Share Dilution 0.2%
- Net Margin Trend 13.5% vs 10.1%
- Piotroski F-Score 6/9
Échoué (9)
- EPS CAGR 1.63%
- Price CAGR 2.52%
- ROIC 4.0%
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- PEG Ratio 2.01
Indisponible (1)
- Dividend Payout NaN%
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Albert G. White III | President, CEO & Non-Independent Director | 55 |
| Mr. Brian G. Andrews | Executive VP, CFO & Principal Accounting Officer | 46 |
| Mr. Daniel G. McBride Esq. | Executive VP, COO General Counsel & Secretary | 61 |
| Ms. Holly R. Sheffield | President of CooperSurgical, Inc. | 54 |
| Mr. Gerard H. Warner III | President of CooperVision, Inc. | 60 |
| Mr. Kim Duncan | Vice President of Investor Relations & Risk Management | - |
Risque d'audit
10
Risque du conseil
3
Risque de rémunération
9
Risque droits des actionnaires
3
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2025-12-05
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-09-09
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-09
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for COO, sourced from Markets Gazette.
- 6/4/2026NEUTRALFull Transcript: Cooper Companies Q2 2026 Earnings Call
The Cooper Companies (COO) released its Q2 2026 earnings call transcript. While the transcript itself is a factual record of the discussion, it does not contain immediate financial results or forward-looking guidance that would directly impact the stock price. Investors will need to analyze the content of the call, including management's commentary on performance, market conditions, and future outlook, to derive actionable insights. The transcript serves as a source document for deeper fundamental analysis rather than an immediate trading signal.
- 3/5/2026NEUTRALCooper (COO) Q1 2026 Earnings Call Transcript
The Q1 2026 earnings call transcript for Cooper Industries plc (COO) has been released. This document provides details on financial performance, business strategies, and future outlook. While specific figures are not available in this summary, earnings call transcripts are crucial for investors to assess a company's financial health, understand challenges and opportunities, and gain insights into future guidance. A thorough analysis of this transcript could reveal signals of growth or slowdown.
- 3/5/2026NEUTRALCooper Companies Earnings Review: Q1 Summary
Cooper Companies Inc. released its first-quarter results, showing performance in line with analyst expectations. Revenue stood at $920 million, up 6% year-over-year, while adjusted earnings per share came in at $3.80, matching the consensus. The Vision Care division led growth with a 7% increase, while the Women's Health division saw a 5% rise. Guidance for the second quarter was reaffirmed, indicating a stable outlook. For investors, the news confirms the resilience of Cooper Companies' business model, but without any surprises to trigger significant stock movement.
via Markets Gazette